Zinger Key Points
- “The Fundamentals of PAT” is now taking registrations and will start May 2023.
- Upon full completion of all Pathway courses, participants will be awarded a formal certificate.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Mental healthcare company Numinus Wellness Inc. NUMIF is launching a collection of psychedelic-assisted therapist (PAT) training courses for practitioners with multi-modal teaching methods.
Since the fall of 2022, more than 200 practitioners have completed the different practitioner training courses on PAT fundamentals, molecular foundations, and practical applications, CEO Payton Nyquvest says.
The new Numinus Certification Pathway allows therapists and medical professionals to learn PAT protocols and interact with practitioners sharing real-life experiences in providing integrative and transformative mental wellness.
The new Certification Pathway has an average 30 spaces available to external practitioners in each course offered. Upon each course completion, practitioners are given a certificate recognized by several Canadian and U.S. accreditation bodies.
Upon full completion of all Pathway courses, participants will be awarded a formal certificate to designate competency in providing PAT for the specific medicine.
The core component of the Certification Pathway, “The Fundamentals of PAT,” is now taking registrations and will start May 2023.
Chief Clinical Officer’s Participation In Peer-Reviewed Publications
Numinus chief clinical officer Reid Robison has made contributions to studies published in peer-reviewed papers through his work in the psychedelic-assisted treatment of mental health disorders (i.e., PTSD, depression and anxiety).
The publications encompass:
-
Ketamine-assisted group therapy for frontline healthcare workers with COVID-related burnout and PTSD (in the Journal of Psychoactive Drugs);
-
Cannabis-assisted therapy for complex dissociative PTSD (in Frontiers in Psychiatry);
-
A review on clinical trials on ketamine and esketamine for treatment-resistant depression (TRD) (in the Journal of Psychedelic Studies)
Benzinga’s PCC
Benzinga’s Psychedelics Capital Conference is next up!
Taking place at the Fontainebleau Miami Beach Hotel on April 13, 2023, the event’s THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.
Get your tickets now and don’t miss out!
Photo by Fa Barboza on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!